10-Q: Akebia Returns to Profit Amid Strong Vafseo Launch

Akebia Therapeutics reported a return to net income and significant revenue growth for the nine months ended September 30, 2025, driven by the successful U.S. launch of Vafseo, despite the loss of exclusivity for Auryxia.

Summary

• Total revenues increased by 57% to $178.6 million for the nine months ended September 30, 2025, compared to $113.7 million in the prior year period.
• Product revenue, net, grew 61% to $173.0 million, with Vafseo contributing $39.6 million since its U.S. market entry in January 2025.
• Auryxia product revenue increased by 23.7% to $133.4 million for the nine months, despite losing exclusivity in March 2025.
• The company achieved a net income of $6.9 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $46.6 million in the same period last year.
• Cash and cash equivalents substantially increased to $166.4 million as of September 30, 2025, from $51.9 million at December 31, 2024.
• Operating activities generated $36.9 million in cash for the nine months, compared to a cash usage of $36.2 million in the prior year.
• Research and development expenses rose by 38% to $35.7 million, primarily due to increased Vafseo clinical trial activities and headcount.
• Selling, general and administrative expenses increased by 3% to $81.4 million, driven by Vafseo U.S. launch marketing costs and higher headcount.
• The company does not plan to initiate the VALOR clinical trial for a broad label of Vafseo for non-dialysis dependent CKD patients, following a Type C meeting with the FDA.
• Enrollment in the post-approval pediatric study for Auryxia's hyperphosphatemia indication has been halted based on FDA recommendations due to challenges.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with a return to profitability and significant revenue growth driven by a successful new product launch. However, ongoing regulatory challenges for label expansion and a material weakness in internal controls temper the overall positive sentiment.

Positives

• Achieved net income of $6.9 million for the nine months ended September 30, 2025, a substantial turnaround from a $46.6 million net loss in the prior year.
• Total revenues increased significantly by 57% to $178.6 million, demonstrating strong top-line growth.
• Successful U.S. market entry of Vafseo in January 2025, generating $39.6 million in product revenue in its first nine months.
• Auryxia sales increased by 23.7% to $133.4 million for the nine months, even after losing exclusivity in March 2025, partially due to an authorized generic version.
• Cash and cash equivalents grew to $166.4 million, providing a stronger liquidity position.
• Operating activities generated $36.9 million in cash, indicating improved operational efficiency and cash flow generation.
• Secured $10.0 million in additional debt funding from the BlackRock Credit Agreement's Tranche C in February 2025, extending the maturity date to January 29, 2028.
• Successfully raised $46.5 million net from a public offering in March 2025 and an additional $1.6 million from the underwriters' option in April 2025.

Negatives

• The company will not pursue a broad label for Vafseo for non-dialysis dependent CKD patients, as alignment with the FDA on the VALOR clinical trial design was not reached.
• Enrollment in the post-approval pediatric study for Auryxia has been halted due to enrollment and retention challenges, with further discussions planned with the FDA.
• Auryxia lost exclusivity in the U.S. in March 2025, which is expected to negatively impact future revenues, despite the current offset from an authorized generic.
• A material weakness in internal control over financial reporting related to inventory accounting was identified as of December 31, 2024, and remediation efforts are ongoing.
• Increased R&D expenses by 38% and SG&A expenses by 3% for the nine months ended September 30, 2025, reflecting higher operational costs.

Risks

• Incurred significant losses since inception and cannot guarantee future profitability, with an accumulated deficit of $1.7 billion as of September 30, 2025.
• May require substantial additional financing to fund business, and failure to obtain capital on acceptable terms could delay or terminate product development/commercialization.
• Raising additional capital may dilute existing stockholders, restrict operations, or require relinquishing rights to products on unfavorable terms.
• Business is substantially dependent on the commercial success of Auryxia and Vafseo, and inability to maintain successful commercialization will materially harm financial condition.
• Failure to obtain or maintain adequate coverage, pricing, and reimbursement for Auryxia, Vafseo, or future approved products could adversely impact sales and profitability.
• Faces substantial competition, which may result in others discovering, developing, or commercializing products more successfully.
• Commercialization outside the U.S. subjects the company to risks associated with international operations, including political, regulatory, and economic instability.
• Clinical drug development is lengthy, expensive, and uncertain, with potential for delays or inability to complete development of product candidates.
• Auryxia, Vafseo, or other product candidates may cause undesirable side effects or have other properties that delay or prevent marketing approval or limit commercial potential.
• May not obtain marketing approval for Vafseo label expansion or other product candidates, or may experience significant delays.
• Products approved for marketing are subject to extensive post-marketing regulatory requirements, including post-approval pediatric studies, and could face restrictions or withdrawal.
• Subject to complex regulatory schemes (e.g., anti-kickback, false claims, data privacy) requiring significant resources, with non-compliance leading to fines or sanctions.
• Significant liability if promoting off-label use of products or improper direct-to-consumer advertising, or violations of the federal Anti-Kickback Statute.
• Disruptions at the FDA and other government agencies (funding cuts, personnel losses, shutdowns) could hinder timely guidance and approval of product candidates.
• Legislative and regulatory healthcare reform may increase difficulty and cost of obtaining marketing approval and commercializing products, affecting prices.
• Dependence on collaborations with third parties for development and commercialization of Auryxia, authorized generic Auryxia, Riona, and Vafseo; failure or termination of collaborations could harm business.
• Reliance on third parties to conduct clinical trials and preclinical studies; failure to carry out duties or comply with regulations could substantially harm business.
• If the licensor of certain intellectual property relating to Auryxia terminates or modifies contracts, business may be materially harmed.
• Changes in U.S. trade policy on tariffs and geopolitical environment (e.g., with China, Europe, Canada) may adversely impact business and operating results, especially with international manufacturers.
• Inability to adequately protect intellectual property could allow third parties to use it, adversely affecting market competition.
• Intellectual property and non-patent exclusivity for current and future products may be limited, affecting competitive ability and product value.
• Market entry of generic competitors or challenges to intellectual property rights will likely limit Auryxia and Vafseo sales.
• Litigation and administrative proceedings (e.g., intellectual property infringement, opposition proceedings) may be costly, time-consuming, and delay drug development/commercialization.
• Material weakness in internal control over financial reporting as of December 31, 2024, relating to inventory accounting; failure to remediate could impact financial reporting accuracy and fraud prevention.
• Stock price has been and may continue to be volatile, potentially leading to substantial losses for stockholders and lawsuits.
• Failure to comply with Nasdaq listing requirements could result in delisting, negatively impacting stock price and capital access.
• Issuance of additional common stock or sales by significant stockholders will dilute ownership and may cause stock price decline.
• Provisions in organizational documents and Delaware law may have anti-takeover effects, discouraging acquisitions.
• No anticipated cash dividends; capital appreciation is the sole source of gain for stockholders.
• Ability to use net operating losses to offset future taxable income may be subject to limitations under Section 382 of the Internal Revenue Code.
• Security breaches and unauthorized use of IT systems could damage clinical trials, impact regulatory filings, compromise intellectual property, and lead to significant fines.

Future Outlook

The company believes its existing cash resources and expected cash generation from product, royalty, supply, and license revenues are sufficient to fund its current operating plan for the foreseeable future, including commercializing Vafseo and Auryxia and advancing existing programs. However, this is contingent on achieving anticipated Vafseo revenue projections. The company does not plan to pursue a broad label for Vafseo for non-dialysis dependent CKD patients but will maintain dialogue with the FDA for a potential smaller subgroup. Future cash needs may be financed through additional equity sales, new debt transactions, strategic transactions, or other cash-generating measures.

Management Comments

• We believe our existing cash resources and the cash we expect to generate from product, royalty, supply and license revenues are sufficient to fund our current operating plan for the foreseeable future, including to commercialize Vafseo and Auryxia and advance our existing programs.
• We believe the dynamics of Auryxia reimbursement being included in the ESRD bundle could result in a slower revenue decline after the LoE date than in other LoE situations.
• We expect our cost of product and other revenue for Vafseo will increase, reflecting the full cost of manufacturing, subsequent to the utilization of our reduced-cost Vafseo inventory.
• We expect to incur significant R&D expenses in future periods in support of ongoing or planned studies with respect to the development of our product candidates as well as Vafseo.
• We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.

Industry Context

Akebia operates in the highly competitive biopharmaceutical industry, specifically targeting kidney disease. The U.S. market for anemia due to CKD in dialysis patients is approximately $1 billion, with Vafseo being the only oral HIF-based treatment. The phosphate binder market, where Auryxia competes, has seen a reduction in growth since early 2020, partly due to the COVID-19 pandemic's disproportionate impact on CKD patients and labor shortages in dialysis providers. Regulatory changes, such as the inclusion of oral-only phosphate binders in the ESRD bundle and the Inflation Reduction Act's drug pricing provisions, are significantly shaping the market landscape and reimbursement models. The company faces competition from established players like Amgen, Roche, and GSK, as well as new therapies and generic entrants.

Comparison to Industry Standards

• Vafseo's U.S. market entry as the only oral HIF-based treatment for anemia due to CKD in dialysis patients positions it uniquely against injectable erythropoiesis stimulating agents (ESAs) like Amgen's Epogen/Aranesp and Johnson & Johnson's Procrit/Eprex.
• The 61% increase in product revenue and return to net income for the nine months ended September 30, 2025, suggests strong commercial execution, particularly with a new product launch, compared to many smaller biopharmaceutical companies that often remain unprofitable for longer periods post-launch.
• Auryxia's continued revenue growth (23.7% increase) despite losing exclusivity in March 2025, and the presence of an authorized generic, indicates a potentially more resilient performance than typical post-LoE scenarios for other branded drugs, which often see rapid and steep declines.
• The company's ability to secure commercial supply agreements for Vafseo with dialysis organizations caring for nearly 100% of U.S. dialysis patients is a strong indicator of market penetration and competitive positioning against existing therapies.
• The decision not to pursue a broad label for Vafseo in non-dialysis dependent CKD patients, while a setback, aligns with a more focused strategy, potentially reducing R&D burn compared to competitors pursuing broader indications without clear regulatory pathways.

Corporate Governance

Legal Proceedings

• Dr. Reddy's Laboratories Limited filed an opposition to Indian Patent No. 287720 covering vadadustat composition of matter in September 2018; amended claims published May 9, 2025.
• Sandoz AG filed an opposition against European Patent No. 3007695 covering vadadustat once daily dosing regimen in November 2024; oral proceedings scheduled for February 24-25, 2026.
• Ardelyx, Inc. filed a complaint against HHS, CMS, and other parties in July 2024, alleging that CMS's plan to include oral-only phosphate lowering therapies in the ESRD PPS violated statutory authority. The district court denied a preliminary injunction and granted dismissal, but Ardelyx appealed. Oral argument was held on September 25, 2025, and the case was transferred to the Eastern District of Missouri on September 30, 2025.
• Various lawsuits filed by Merck & Co. Inc., U.S. Chamber of Commerce, Bristol Myers Squibb Company, PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca, Boehringer Ingelheim, and Teva challenging the IRA's Drug Price Negotiation Program for Medicare. Most cases are on appeal, with some substantive disputes won by HHS.

Related Party Transactions

• CSL Vifor (now part of CSL Limited) holds 7,571,429 shares of common stock, which were issued in connection with the Original License Agreement and Vifor License Agreement. The company also has a liability related to settlement royalties and a Working Capital Fund liability with CSL Vifor.
• HealthCare Royalty Partners IV, L.P. (HCR) is a party to a royalty interest acquisition agreement, having purchased the company's right to receive royalties and sales milestones for Vafseo in Japan and certain other Asian countries, subject to caps.

Stakeholder Impact

• Shareholders: Potential for increased value due to return to profitability and strong Vafseo launch, but also dilution from recent capital raises and ongoing risks from Auryxia LoE and regulatory uncertainties.
• Patients: Vafseo's U.S. launch provides a new oral treatment option for anemia in dialysis-dependent CKD patients. However, the halted pediatric study for Auryxia and the decision not to pursue a broad NDD-CKD label for Vafseo may limit treatment options for certain patient populations.
• Employees: Increased headcount related to Vafseo launch and R&D activities, but also past workforce reductions and ongoing competition for qualified personnel.
• Dialysis Organizations: Continued engagement through commercial supply agreements for Vafseo and Auryxia, but also potential impact from changes in reimbursement models (ESRD bundle, TDAPA) and competition.
• Collaboration Partners (Medice, MTPC, JT and Torii, AG Partner): Continued revenue generation from licensed products, but also reliance on their commercialization success and potential for disputes or termination of agreements.

Next Steps

• Continue commercialization activities for Vafseo and Auryxia in the U.S.
• Advance existing pipeline programs and explore additional development opportunities.
• Maintain dialogue with the FDA regarding a potential smaller subgroup of CKD non-dialysis dependent patients for Vafseo.
• Request a meeting with the FDA to discuss the halted enrollment in the Auryxia pediatric study.
• Continue remediation efforts for the material weakness in internal control over financial reporting related to inventory accounting.
• Monitor and adapt to legislative and regulatory healthcare reforms, including the Inflation Reduction Act and potential changes from the Trump Administration's policies.
• Manage and comply with the terms of the BlackRock Credit Agreement, including interest-only payments until December 31, 2026, and subsequent principal payments.
• Address potential impacts from U.S. trade policies and legislation (e.g., BIOSECURE Act) on manufacturing and supply chain, particularly with Chinese partners.

Key Dates

Recommendation

Akebia Therapeutics has demonstrated a significant turnaround, achieving net income and robust revenue growth driven by the successful U.S. launch of Vafseo. The substantial increase in cash and cash equivalents strengthens its financial position. However, the long-term impact of Auryxia's loss of exclusivity remains a key uncertainty, and the decision not to pursue a broad label for Vafseo in non-dialysis dependent CKD patients limits a significant growth opportunity. Ongoing regulatory challenges, including the halted pediatric study and a material weakness in internal controls, add layers of risk. While the current performance is strong, these uncertainties warrant a 'hold' recommendation, suggesting investors monitor the company's ability to mitigate these risks and expand its pipeline effectively.

Keywords

Akebia Therapeutics, Vafseo, Auryxia, CKD, Anemia, Dialysis, HIF-PH inhibitor, Ferric Citrate, Biopharmaceutical, SEC Filing, 10-Q, Financial Results, Product Launch, Generic Competition, FDA Approval, Clinical Trials, Pharmaceutical, Kidney Disease, Vadadustat, Riona